SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
#2812
Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).
Aim(s): The present retrospective multicenter project is analyzing the predictive/prognosis role of MGMT, NDRG-1 and PHLDA-3 in patients treated with advanced PanNET treated CAPTEM or everolimus.
Materials and methods: IHC nuclear staining for MGMT and PHLDA-3 is being scored as 0, 1-5%, 6-50% and ≥ 51%. For NDRG-1, we are using a cytoplasmic score from 0 to 2 based on distribution pattern (', patched or diffuse).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Viudez A
Authors: Viudez A, Crespo G, Gómez-Dorronsoro M, Benavent M, Hernando J,
Keywords: biomarker, PHLDA3, MGMT, IHC, NDRG1, CAPTEM, everolimus,
To read the full abstract, please log into your ENETS Member account.